Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by fossi_2002on Dec 14, 2023 9:24am
179 Views
Post# 35784121

plenty of cash?

plenty of cash?Ciao,

Aeterna's shareholders will be paid extra for the 38 million cash!

I doubt whether we will be able to pay the development costs of PGX. In the first 9 months alone, Aeterna suffered a loss of around 11 million. If you include a further 3.5 million loss for the 4th quarter, the year-end balance is 35 million cash. In 2024 at least another 15 mill. loss plus the loss from Ceapro - so the money is running out fast.
In an initial reaction, Aeterna rose to 3$ on the NASDAQ and is now trading at 2.15$ with a MINUS.




<< Previous
Bullboard Posts
Next >>